{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:53:03Z","timestamp":1762249983554,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004061","name":"Austrian National Bank","doi-asserted-by":"publisher","award":["16433"],"award-info":[{"award-number":["16433"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109431","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:50:03Z","timestamp":1755496203000},"page":"109431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events"],"prefix":"10.1016","volume":"254","author":[{"given":"Rafaela","family":"Vostatek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taras","family":"Afonyushkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ozsvar","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Klauser-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109431_bb0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109431_bb0010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2025.109431_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semnephrol.2016.12.002","article-title":"Evolution of cardiovascular disease during the transition to end-stage renal disease","volume":"37","author":"Bansal","year":"2017","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0020","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192895","article-title":"Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis","volume":"13","author":"Major","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.thromres.2025.109431_bb0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000485842","article-title":"Long-term survivor characteristics in hemodialysis patients with type 2 diabetes","volume":"47","author":"Triebswetter","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ai.2016.02.001","article-title":"Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis","volume":"131","author":"Papac-Milicevic","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.thromres.2025.109431_bb0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nri.2016.63","article-title":"Innate sensing of oxidation-specific epitopes in health and disease","volume":"16","author":"Binder","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.thromres.2025.109431_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.13874","article-title":"Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease","volume":"16","author":"Eichinger","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109431_bb0050","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2020007155","article-title":"Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis","volume":"137","author":"Obermayer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109431_bb0055","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jth.13925","article-title":"Oxidized low-density lipoprotein in inflammation-driven thrombosis","volume":"16","author":"Obermayer","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109431_bb0060","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jacc.2012.08.979","article-title":"Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2025.109431_bb0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0003319713512720","article-title":"Relationship between oxidized LDL, IgM, and igg autoantibodies to ox-ldl levels with recurrent cardiovascular events in swedish patients with previous myocardial infarction","volume":"65","author":"Crisby","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.thromres.2025.109431_bb0070","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2025.109431_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/ATVBAHA.124.319843","article-title":"Role of antibodies and their specificities in atherosclerotic cardiovascular disease","volume":"44","author":"Deroissart","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2025.109431_bb0080","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1111\/jth.15508","article-title":"Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: from the VIVALDI, a population-based prospective cohort study","volume":"19","author":"K\u00f6nigsbr\u00fcgge","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109431_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0090","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and m\u00f6nckeberg\u2019s sclerosis: a continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0095","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","article-title":"Oxidative stress is progressively enhanced with advancing stages of CKD","volume":"48","author":"Dounousi","year":"2006","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.thromres.2025.109431_bb0100","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ndt\/gfn489","article-title":"Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients","volume":"24","author":"Cottone","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.thromres.2025.109431_bb0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacl.2018.07.010","article-title":"The CKD plasma lipidome varies with disease severity and outcome","volume":"13","author":"Duranton","year":"2019","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.thromres.2025.109431_bb0115","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/toxins8120376","article-title":"Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins","volume":"8","author":"Florens","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.thromres.2025.109431_bb0120","first-page":"2544","article-title":"Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies","volume":"117","author":"Porsch","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.thromres.2025.109431_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCRESAHA.110.223875","article-title":"Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity","volume":"108","author":"Miller","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.thromres.2025.109431_bb0130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.2008.01968.x","article-title":"Oxidation-specific epitopes are important targets of innate immunity","volume":"263","author":"Chou","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2025.109431_bb0135","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20031763","article-title":"Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory","volume":"200","author":"Chang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.thromres.2025.109431_bb0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1194\/jlr.P054569","article-title":"Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies","volume":"56","author":"Tsiantoulas","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.thromres.2025.109431_bb0145","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1172\/JCI36800","article-title":"Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans","volume":"119","author":"Chou","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2025.109431_bb0150","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.thromres.2025.109431_bb0155","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.bbamem.2012.01.018","article-title":"The innate immune response to products of phospholipid peroxidation","volume":"1818","author":"Weismann","year":"2012","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.thromres.2025.109431_bb0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5301\/JN.2011.6442","article-title":"OxPL\/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients","volume":"24","author":"Bossola","year":"2011","journal-title":"J. Nephrol."},{"key":"10.1016\/j.thromres.2025.109431_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s40885-023-00240-x","article-title":"Diagnosis and treatment of hypertension in dialysis patients: a systematic review","volume":"29","author":"Kim","year":"2023","journal-title":"Clin. Hypertens."},{"key":"10.1016\/j.thromres.2025.109431_bb0170","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa013591","article-title":"Endothelial function and oxidative stress in renovascular hypertension","volume":"346","author":"Higashi","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109431_bb0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/01.HYP.0000138070.47616.9d","article-title":"Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?","volume":"44","author":"Touyz","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.thromres.2025.109431_bb0180","article-title":"Oxidative mechanisms and cardiovascular abnormalities of cirrhosis and portal hypertension","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.thromres.2025.109431_bb0185","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jbmr.2420","article-title":"Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification","volume":"30","author":"Sheen","year":"2015","journal-title":"J. Bone Miner. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:41:02Z","timestamp":1762249262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825001811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S0049384825001811"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109431","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109431"}}